Imagine #Barcelona with an additional 8 degrees in summer 🔥 🔥🔥 Session: Disaster Medicine - Impact of climate change, heat, and global insecurity #EULAR2025 @RheumNow https://t.co/1TqlBJtoZD

RA is worst with temperature rising/ climate change. However SpA has the opposite effect! Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD

Tips for Dx RP: 1. Suspect the dx and recognize chondritis. 2. Rule out mimickers 3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA) 4. CV, heme, derm manifestations 🧐VEXAS. 5. biopsy not useful unless ≠ from GCA. Fantastic session by @Lupusreference https://t.co/W4DgfeRULF

#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl

What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory? Rx Retro study 388 patients RA 18% at least one sign CPPD ns diff between seeonegative and seropositive pts RA+CPPD group was -older -higher comorbidity score -more likely to be https://t.co/DaW5DZoDzF

Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 https://t.co/HtHyADsOSX

Climate Change Impacts #Rheumatology Care Taking HEAT 🥵 causes: 🔺️⬆️ Hospitalisations 🔺️Renal failure ⚠️ NSAIDs 🔺️Flooding: no access to healthcare 🔺️New Infectious diseases mimics RMDs: Zika... 🔺️Insecurities for drug storage and transportation #EULAR2025 @RheumNow https://t.co/V9RyxYX6Me

APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3

#GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN

Genicular artery embolisation is like so many interventions in MSK medicine: early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit. If you do meta-analyses of all these data, you mix good with bad #EULAR2025 @RheumNow https://t.co/K1tN9KX8rq

Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT

Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z